These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36578502)
1. Longevity of memory B cells and antibodies, as well as the polarization of effector memory helper T cells, are associated with disease severity in patients with COVID-19 in Bangladesh. Akhtar M; Basher SR; Nizam NN; Kamruzzaman M; Khaton F; Banna HA; Kaisar MH; Karmakar PC; Hakim A; Akter A; Ahmed T; Tauheed I; Islam S; Ahmmed F; Mahamud S; Hasnat MA; Sumon MA; Rashed A; Ghosh S; Calderwood SB; Harris JB; Charles RC; LaRocque RC; Ryan ET; Banu S; Shirin T; Chowdhury F; Bhuiyan TR; Qadri F Front Immunol; 2022; 13():1052374. PubMed ID: 36578502 [TBL] [Abstract][Full Text] [Related]
2. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Sherina N; Piralla A; Du L; Wan H; Kumagai-Braesch M; Andréll J; Braesch-Andersen S; Cassaniti I; Percivalle E; Sarasini A; Bergami F; Di Martino R; Colaneri M; Vecchia M; Sambo M; Zuccaro V; Bruno R; Sachs M; Oggionni T; Meloni F; Abolhassani H; Bertoglio F; Schubert M; Byrne-Steele M; Han J; Hust M; Xue Y; Hammarström L; Baldanti F; Marcotte H; Pan-Hammarström Q Med; 2021 Mar; 2(3):281-295.e4. PubMed ID: 33589885 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417 [TBL] [Abstract][Full Text] [Related]
4. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA; Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598 [TBL] [Abstract][Full Text] [Related]
5. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection. Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754 [TBL] [Abstract][Full Text] [Related]
6. Detection of specific RBD Del Pino Molina L; Bravo Gallego LY; Nozal P; Soto-Serrano Y; Martínez-Feito A; Reche-Yebra K; González-Torbay A; Cuesta-Martín de la Cámara R; Gianelli C; Cámara C; González-García J; González-Muñoz M; Rodríguez-Pena R; López Granados E Front Immunol; 2023; 14():1136308. PubMed ID: 37215146 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. Reyes RA; Clarke K; Gonzales SJ; Cantwell AM; Garza R; Catano G; Tragus RE; Patterson TF; Bol S; Bunnik EM PLoS One; 2021; 16(12):e0261656. PubMed ID: 34936684 [TBL] [Abstract][Full Text] [Related]
8. Memory B-Cell Development After Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection. Kato Y; Bloom NI; Sun P; Balinsky CA; Qiu Q; Cheng Y; Jani V; Schilling MA; Goforth CW; Weir DL; Ramos I; Sealfon SC; Letizia AG; Crotty S J Infect Dis; 2022 Dec; 227(1):18-22. PubMed ID: 35892131 [TBL] [Abstract][Full Text] [Related]
9. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Hartley GE; Edwards ESJ; Aui PM; Varese N; Stojanovic S; McMahon J; Peleg AY; Boo I; Drummer HE; Hogarth PM; O'Hehir RE; van Zelm MC Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33443036 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009 [TBL] [Abstract][Full Text] [Related]
11. High activation levels maintained in receptor-binding domain-specific memory B cells in people with severe coronavirus disease 2019. Gupta M; Balachandran H; Louie RHY; Li H; Agapiou D; Keoshkerian E; Christ D; Rawlinson W; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Bartlett AW; Sasson SC; Ahlenstiel G; Dwyer D; Lloyd AR; Martinello M; Luciani F; Bull RA; Immunol Cell Biol; 2023 Feb; 101(2):142-155. PubMed ID: 36353774 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination. Moore T; Hossain R; Doores KJ; Shankar-Hari M; Fear DJ Viral Immunol; 2022 Jul; 35(6):425-436. PubMed ID: 35857310 [TBL] [Abstract][Full Text] [Related]
13. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253 [TBL] [Abstract][Full Text] [Related]
14. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525 [TBL] [Abstract][Full Text] [Related]
15. A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials. Bisceglia H; Barrier J; Ruiz J; Pagnon A J Immunol Methods; 2023 Apr; 515():113457. PubMed ID: 36914088 [TBL] [Abstract][Full Text] [Related]